Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994.[A178975] It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile.[A179098] Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia.[A179098] Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.[L6582][L6583][L7309][L7312]
Naproxen Sodium and Pseudoephedrine Hydrochloride Sinus and Cold
Foster and Thrive All Day Pain Relief
SALLUS Pain Relief Collection with Naproxen
Naproxen Liquid Gels
Naproxen Sodium BACK AND MUSCLE PAIN
Sunmark All Day Relief
Ana-Dent Toothache Relief
Equate Sinus and Cold D
Naprosyn E 250mg Tablets - Ect
Suvexx
Sinus and Cold D
Flanax Menstrual Pain Reliever
Naproxen and esomeprazole magnesium
Vicks Sinex D Severe Sinus and Cold
PREVACID NapraPAC 250
Rugby All Day Relief
Clear Choice Naproxen Sodium
Naprosyn 375mg Tablets
Careone Naproxen Sodium
Leader Sinus and Cold-D
Naproxen sodium
Pain Relief
Naproxen Delayed-release
Apo-naproxen EC Tablets
Dg Health Naproxen Sodium PM
Pro-naproxen EC - 375
Ntp-naproxen
Signature Care Pain Relief
Teva-naproxen SR
Naproxen Sodium Capsules
Healthy Accents Naproxen Sodium
Naprosyn 375mg
Indication
Naproxen is indicated for the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain.[L6582][L6583][A178975] Further, it is first-line therapy for osteoarthritis, acute gouty arthritis, dysmenorrhea, and musculoskeletal inflammation and pain.[A178975]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682